Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles

Antonella Caccamo, Salvatore Oddo, Lana X. Tran, Frank M. LaFerla

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3α and GSK-3β. In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3α may regulate amyloid precursor protein processing and Aβ formation. The activities of both GSK-3α and GSK-3β are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the Aβ load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on Aβ and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-Aβ interventions.

Original languageEnglish (US)
Pages (from-to)1669-1675
Number of pages7
JournalAmerican Journal of Pathology
Volume170
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Memory Disorders
Short-Term Memory
Lithium
Phosphorylation
Alzheimer Disease
Combat Disorders
Therapeutics
Serum Amyloid A Protein
Amyloid beta-Protein Precursor
Bipolar Disorder
Biochemistry
Phosphotransferases
Clinical Trials
Learning
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. / Caccamo, Antonella; Oddo, Salvatore; Tran, Lana X.; LaFerla, Frank M.

In: American Journal of Pathology, Vol. 170, No. 5, 05.2007, p. 1669-1675.

Research output: Contribution to journalArticle

@article{c4f7ab78c9ca47bcaec0f4f3c44130e0,
title = "Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles",
abstract = "Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3α and GSK-3β. In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3α may regulate amyloid precursor protein processing and Aβ formation. The activities of both GSK-3α and GSK-3β are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the Aβ load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on Aβ and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-Aβ interventions.",
author = "Antonella Caccamo and Salvatore Oddo and Tran, {Lana X.} and LaFerla, {Frank M.}",
year = "2007",
month = "5",
doi = "10.2353/ajpath.2007.061178",
language = "English (US)",
volume = "170",
pages = "1669--1675",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles

AU - Caccamo, Antonella

AU - Oddo, Salvatore

AU - Tran, Lana X.

AU - LaFerla, Frank M.

PY - 2007/5

Y1 - 2007/5

N2 - Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3α and GSK-3β. In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3α may regulate amyloid precursor protein processing and Aβ formation. The activities of both GSK-3α and GSK-3β are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the Aβ load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on Aβ and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-Aβ interventions.

AB - Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3α and GSK-3β. In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3α may regulate amyloid precursor protein processing and Aβ formation. The activities of both GSK-3α and GSK-3β are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the Aβ load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on Aβ and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-Aβ interventions.

UR - http://www.scopus.com/inward/record.url?scp=34250818767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250818767&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2007.061178

DO - 10.2353/ajpath.2007.061178

M3 - Article

VL - 170

SP - 1669

EP - 1675

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -